首页> 美国卫生研究院文献>BMC Medical Ethics >A developing country response to Lavery et al. In global health research is it legitimate to stop clinical trials early on account of their opportunity costs?

【2h】

A developing country response to Lavery et al. In global health research is it legitimate to stop clinical trials early on account of their opportunity costs?

机译：发展中国家对Lavery等的回应。在全球健康研究中由于机会成本而早日停止临床试验是否合法？

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundA recent paper presents an argument and mechanism for the possible stopping of clinical trials early based on opportunity costs.

机译：背景技术最近的一篇论文提出了一种基于机会成本而可能尽早停止临床试验的论点和机制。

著录项

期刊名称 BMC Medical Ethics
作者
Douglas R Wassenaar; Gita Ramjee;
展开▼
作者单位

展开▼
年(卷),期 2009(10),-1
年度 2009
页码 16
总页数 3
原文格式 PDF
正文语种
中图分类病理学;
关键词

相似文献

外文文献
中文文献
专利

1. In Global Health Research, Is It Legitimate To Stop Clinical Trials Early on Account of Their Opportunity Costs? [J] . James V. Lavery, Peter A. Singer, Renee Ridzon, PLoS Medicine . 2009,第6期

机译：在全球卫生研究中，由于他们的机会成本，它是尽早停止临床试验的合法吗？
2. A developing country response to Lavery et al. [J] . Douglas R Wassenaar, Gita Ramjee BMC Medical Ethics . 2009,第1期

机译：发展中国家对Lavery等人的回应。
3. The ethics of global clinical trials In developing countries, participation in clinical trials is sometimes the only way to access medical treatment. What should be done to avoid exploitation of disadvantaged populations? [J] . Weigmann Katrin EMBO reports . 2015,第5期

机译：全球临床试验的道德规范在发展中国家，参与临床试验有时是获得医疗服务的唯一途径。应该采取什么措施避免剥削弱势群体？
4. Global Casting Trends Combating International Competition A SWOT (Strength, Weakness, Opportunity, Threat) Analysis of Low Cost Nations Competing with Developed Countries [C] . Aifred Spada, Chandra Rajan Proceedings of 69th world foundry congress . 2010

机译：全球铸造趋势和应对国际竞争低成本国家与发达国家竞争的SWOT分析（优势，劣势，机会，威胁）
5. Globalisation and corporate governance in developing countries (a micro analysis of global corporate interconnection between developing African countries and developed countries) (Nigeria, Ghana). [D] . Ahunwan, Boniface U. 2002

机译：发展中国家的全球化和公司治理（对非洲发展中国家和发达国家之间全球公司相互联系的微观分析）（尼日利亚，加纳）。
6. In Global Health Research Is It Legitimate To Stop Clinical Trials Early on Account of Their Opportunity Costs? [O] . James V. Lavery, Peter A. Singer, Renee Ridzon, 2009

机译：在全球健康研究中是否由于机会成本而提前停止临床试验是否合法？
7. A developing country response to Lavery et al. "In global health research, is it legitimate to stop clinical trials early on account of their opportunity costs?" [O] . Douglas R Wassenaar, Gita Ramjee 2009

机译：发展中国家对Lavery等的回应。 “在全球健康研究中，由于机会成本而早日停止临床试验是否合法？”
8. Ethical and Policy Issues in International Research: Clinical Trials in Developing Countries. Executive Summary; Volume 1. Report and Recommendations of the National Bioethics Advisory Commission; and Volume 2. Commissioned Papers and Staff Analysis. [R] . 2001

机译：国际研究中的伦理与政策问题：发展中国家的临床试验。执行摘要;第1卷。国家生物伦理咨询委员会的报告和建议;和第2卷。委托论文和工作人员分析。

A developing country response to Lavery et al. In global health research is it legitimate to stop clinical trials early on account of their opportunity costs?

摘要

著录项

相似文献

相关主题

期刊订阅